source
- Roche presents positive Phase 2 results for enicepatide in overweight and obese type 2 diabetes patientsRoche has released new data from a Phase 2 trial of enicepatide, a peptide acquired from Carmot Therapeutics, focusing on overweight or obese adults with type 2 diabetes. The trial met its primary…
- FDA issues third warning letter to Empower Pharmacy over GLP-1 weight-loss treatmentsThe U.S. Food and Drug Administration sent a formal warning letter to Empower Pharmacy, a compounder based in Houston, concerning its GLP-1 weight-loss products. The notice marks the company's thi…